The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
82766785 8276678 5 F 20110627 20160815 20111206 20160818 EXP JP-GLAXOSMITHKLINE-B0739157A GLAXOSMITHKLINE 32.20 YR F Y 27.00000 KG 20160818 MD JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
82766785 8276678 1 PS LAMICTAL LAMOTRIGINE 1 Oral 25 MG, QOD Y U 20241 25 MG TABLET QOD
82766785 8276678 2 SS LAMICTAL LAMOTRIGINE 1 Oral 25 MG, QD Y U 20241 25 MG TABLET QD
82766785 8276678 3 SS OLANZAPINE. OLANZAPINE 1 Oral 200 MG, TID 0 200 MG TID
82766785 8276678 4 C Hydantol PHENYTOIN SODIUM 1 Oral U 0 TABLET
82766785 8276678 5 C DIAMOX SEQUELS ACETAZOLAMIDE 1 Oral U 0 TABLET
82766785 8276678 6 C RIVOTRIL CLONAZEPAM 1 Oral U 0 .5 MG TABLET BID
82766785 8276678 7 C MYSTAN CLOBAZAM 1 Oral U 0 TABLET
82766785 8276678 8 C MYSTAN CLOBAZAM 1 Oral U 0 TABLET
82766785 8276678 9 C L-Cartin LEVOCARNITINE HYDROCHLORIDE 1 Oral U 0 TABLET

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
82766785 8276678 1 Partial seizures with secondary generalisation
82766785 8276678 3 Partial seizures with secondary generalisation
82766785 8276678 4 Partial seizures with secondary generalisation
82766785 8276678 5 Partial seizures with secondary generalisation
82766785 8276678 6 Partial seizures with secondary generalisation
82766785 8276678 7 Partial seizures with secondary generalisation
82766785 8276678 9 Partial seizures with secondary generalisation

Outcome of event

Event ID CASEID OUTC COD
82766785 8276678 HO
82766785 8276678 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
82766785 8276678 Alanine aminotransferase increased
82766785 8276678 Apoptosis
82766785 8276678 Aspartate aminotransferase decreased
82766785 8276678 Basophil count increased
82766785 8276678 Blood lactate dehydrogenase decreased
82766785 8276678 C-reactive protein increased
82766785 8276678 Conjunctival hyperaemia
82766785 8276678 Conjunctivitis
82766785 8276678 Erythema
82766785 8276678 Erythema of eyelid
82766785 8276678 Eye discharge
82766785 8276678 Eyelid erosion
82766785 8276678 Gamma-glutamyltransferase increased
82766785 8276678 Keratitis
82766785 8276678 Lacrimation increased
82766785 8276678 Lip erosion
82766785 8276678 Lymphocyte count decreased
82766785 8276678 Monocyte count decreased
82766785 8276678 Neutrophil percentage increased
82766785 8276678 Ocular hyperaemia
82766785 8276678 Oral mucosa erosion
82766785 8276678 Pyrexia
82766785 8276678 Rash
82766785 8276678 Rash maculo-papular
82766785 8276678 Scab
82766785 8276678 Stevens-Johnson syndrome
82766785 8276678 Tongue coated
82766785 8276678 White blood cell count increased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
82766785 8276678 1 20110530 0
82766785 8276678 2 20110704 0
82766785 8276678 3 2001 0
82766785 8276678 4 2002 20110702 0
82766785 8276678 5 2002 0
82766785 8276678 6 2002 0
82766785 8276678 7 2002 0